Trial Profile
Efficacy and Safety Assessment of T4032 Versus Lumigan in Ocular Hypertensive or Glaucomatous Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms In-SIGHT
- Sponsors Laboratoires Thea
- 27 Jul 2021 Status changed from recruiting to completed.
- 13 May 2021 This trial has been completed in Belgium (End Date: 24 Feb 2021), according to European Clinical Trials Database record.
- 11 May 2021 This trial has been completed in Poland, according to European Clinical Trials Database.